insights_auto
Why is CLLS up 2.80%?
Dive Deeperchevron_right
CLLS:NASDAQ
Cellectis SA
$1.47
arrow_upward
+2.80%(+0.040) 1D
$1.47
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 25, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CLLS...
Open
$1.45
High
$1.48
Low
$1.41
Mkt. cap
102.46M
Avg. vol.
135.17K
Volume
37.74K
52-wk high
$5.48
52-wk low
$1.25
EPS
-$0.65
Beta
2.92
Shares outstanding
72.09M
No. of employees
227
Open
$1.45
High
$1.48
Low
$1.41
Mkt. cap
102.46M
Avg. vol.
135.17K
Volume
37.74K
52-wk high
$5.48
52-wk low
$1.25
EPS
-$0.65
Beta
2.92
Shares outstanding
72.09M
No. of employees
227
News stories
From web sources and news partners
PR Newswire
·
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
www.dars.gov.et
·
2 months ago
CLLS Q1 2026 Earnings: Better-than-Expected EPS as Operating Expenses Improve - EPS Growth Report
Profile
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
About Cellectis SA